Conflict of Interest
Peer-Reviewed · Open Access · Pharmaceutical Research
Conflict of Interest
The International Journal of Pharma Studies is committed to maintaining transparency, fairness, and integrity throughout the pharmaceutical research, peer-review, and publication process. Authors, reviewers, editors, and other individuals involved in the publication process should disclose any conflict of interest that may affect, or may reasonably appear to affect, their objectivity or judgment.
What Is a Conflict of Interest?
A conflict of interest may arise when an individual's personal, professional, financial, academic, or other interests could influence their judgment or create a reasonable perception of bias in relation to a manuscript or publication decision.
In pharmaceutical research, potential conflicts may include financial relationships with pharmaceutical companies, drug manufacturers, biotechnology firms, clinical research organizations, or other organizations with an interest in the research findings.
A conflict of interest does not necessarily indicate misconduct. Disclosure allows potential conflicts to be considered transparently and, where appropriate, managed to protect the integrity of the editorial and peer-review process.
Roles and Responsibilities
Authors
Authors should disclose relevant conflicts of interest associated with their manuscript, including, where applicable:
Research funding, grants, or financial support from pharmaceutical companies or other organizations.
Financial relationships involving drugs, pharmaceutical products, medical devices, or related technologies discussed in the manuscript.
Paid consultancies, advisory roles, honoraria, or employment relationships.
Patent applications, intellectual property rights, royalties, or commercial interests related to the research.
Pharmaceutical industry sponsorship of clinical trials, laboratory investigations, drug development, or other research activities.
Professional, personal, or institutional relationships that could reasonably be perceived as influencing the research or its presentation.
Where no relevant conflict exists, authors should provide a clear Conflict of Interest declaration stating this. Authors should provide this declaration at the time of manuscript submission.
Reviewers
Reviewers should disclose any circumstance that could create an actual or perceived conflict in relation to a manuscript they are invited to review. This may include a recent research collaboration, a close personal relationship, financial ties to a pharmaceutical company involved in the study, or a competing professional or commercial interest.
A reviewer should not participate in the review where a conflict could compromise, or reasonably appear to compromise, the impartiality of the evaluation.
Reviewers must maintain the confidentiality of manuscripts and should not use information obtained through peer review for personal, professional, financial, or other advantage.
Editors and Editorial Team
Editors and members of the editorial team should identify and disclose relevant conflicts that could affect their editorial judgment.
Where a conflict exists, the editor should, where appropriate, recuse themselves from handling the manuscript, and appropriate arrangements may be made to ensure that the manuscript is handled independently and objectively.
Editors should take particular care where manuscripts involve pharmaceutical products, competing drug formulations, clinical trial results, commercial sponsorship, or research findings that may have financial implications for interested organizations.
Disclosure and Transparency
Conflict-of-interest disclosures should be made accurately at the appropriate stage of the submission or publication process.
Disclosure enables the International Journal of Pharma Studies to assess relevant circumstances and, where necessary, take appropriate measures to protect the fairness, independence, and integrity of editorial and peer-review decisions.
Funding sources and relevant financial relationships should be reported transparently where applicable. Disclosure does not automatically disqualify a manuscript from consideration; editorial decisions should remain based on scientific quality, research integrity, and the journal's publication standards.
Undisclosed Conflicts
If a relevant conflict of interest is identified after submission or publication, the International Journal of Pharma Studies may review the circumstances and request clarification or an appropriate disclosure from the individuals concerned.
Where necessary, the journal may take further action in accordance with its applicable editorial and publication policies. Possible actions may include requesting a disclosure statement, correcting the published record, or taking other appropriate editorial measures based on the circumstances.
Responsibility
Authors, reviewers, editors, and other relevant participants share responsibility for providing complete and truthful disclosures of conflicts of interest.
Failure to disclose a relevant conflict may be considered when assessing the integrity of the submission, review, or publication process.
Policy Review
The International Journal of Pharma Studies may review and update this policy periodically to ensure that it remains consistent with recognized standards, research integrity principles, and responsible practices in pharmaceutical and scholarly publishing.